Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYGNDI)

Drug Name

LMP1-CAR-T cells Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Nasopharyngeal carcinoma	2B6B	Phase 1/2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Epstein-Barr virus Latent membrane protein 1 (EBV LMP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LMP-1/LMP-2 CTLs	DMZU2G1	Lymphoma	2A80-2A86	Phase 1	[2]
Ad5f35-LMPd1-2-transduced autologous dendritic cells	DMQW612	Nasopharyngeal carcinoma	2B6B	Investigative	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Epstein-Barr virus Latent membrane protein 1 (EBV LMP1)	TT0BI4Q	LMP1_EBVG	CAR-T-Cell-Therapy	[1]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02980315) A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application
2	In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma. 2006 May;47(5):837-42.
3	CA patent application no. 876139, Nanotherapeutics for drug targeting.